In this work, we place the transcription factor HIF2α within the molecular circuitry of the AML differentiation block and propose that HIF2α inhibition may add therapeutic efficacy to differentiation therapy for AML treatment thus broadening the therapeutic horizon of ATRA beyond APL. The gene discussed is EPAS1; the disease is acute myeloid leukemia.